Work

Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma

Year: 2026
Type: article
Abstract: PURPOSE: Predictive biomarkers for combined PD-1/CTLA-4 blockade in metastatic melanoma remain limited. We analyzed pretreatment proteogenomic data to define response and resistance biology. EXPERIMENTAL DESIGN: We profiled 208 pretreatment FFPE specimens from patients with metastatic cutaneous melanoma treated across 12 institutions, including 164 receiving dual PD-1+CTLA-4 blockade (Discovery, n=97; Validation 1, n=67) and 44 receiving PD-1 monotherapy. Tumors underwent TMT-based proteomics, RNA sequencing, and targeted/low-pass whole-genome sequencing. Pathway clustering, survival modeling, deconvolution, and machine-learning classification defined and validated subtype signatures. RESULTS: Proteomic pathway clustering identified three reproducible ICI subtypes: immune-enriched ICI-sensitive, ribosome-high, and EMT-like/stromal-enriched. Subtypes stratified progression-free survival after dual ICI in the Discovery (P=0.01) and Validation 1 cohorts (P=0.02). The ICI-sensitive subtype had the highest responder fraction (74% and 73%), compared with ribosome-high (67% and 60%) and EMT-like tumors (44% and 43%) in the Discovery and Validation 1 cohorts, respectively. Subtype-outcome associations were consistent with previous immunotherapy datasets, with pooled hazard ratios ≈0.5-0.8 for immune-enriched tumors. Subtypes plus clinical variables predicted 3-year progression/death better than clinical variables alone in Validation 1 (AUC 0.80 vs 0.64). A 127-protein classifier recapitulated subtype membership in Validation 1 (AUC 0.89-0.97) and predicted 3-year progression/death with AUC 0.79. Subtypes reflected distinct immune, translational, and stromal/ECM programs and nominated POLR3A-associated biology as a candidate resistance axis. CONCLUSIONS: Proteomic pathway states define reproducible, biologically interpretable melanoma subtypes associated with differential benefit from dual PD-1/CTLA-4 blockade. A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy trials.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7235707608
FWCI: 2.071
Cites: 73
Cited by: 1
Related to: 10